Keywords: AstraZeneca, Bristol-Myers Squibb, Kombiglyze, Type 2 diabetes, USA, FDA
US FDA clears AstraZeneca/Bristol-Myers combo diabetes drug Kombiglyze XR
Article | 08 November 2010
The US Food and Drug Administration approved Kombiglyze XR, a drug resulting from a 2007 collaboration between drug majors Anglo-Swedish firm ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Is failure to adopt business process management putting the pharma industry at risk?
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
